Table 3. Distribution of markers (TERT and IDH mutations, 1p/19q complete co-deletion, ATRX loss, TP53 and EGFR expression) for each diagnosis. 1p/19q status according to the criteria discussed throughout the manuscript.
| IDH mutation | TERT mutation | Compl. 1p/19q co-del | ATRX loss | TP53 expression | EGFR expression | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Astrocytic tumors | 21/80 | 26% | 37/72 | 51% | 1/68 | 1% | 24/78 | 31% | 38/80 | 48% | 47/77 | 61% |
| – Astrocytoma | 13/31 | 42% | 15/29 | 52% | 0/27 | 0% | 14/30 | 47% | 11/31 | 35% | 18/29 | 62% |
| – Anaplastic astrocytoma | 8/49 | 16% | 22/43 | 51% | 1/41 | 2% | 10/48 | 21% | 27/49 | 55% | 29/48 | 60% |
| Oligoastrocytic tumors | 46/54 | 85% | 37/54 | 69% | 17/53 | 32% | 25/53 | 47% | 30/53 | 57% | 34/53 | 64% |
| – Oligoastrocytoma | 22/26 | 85% | 17/26 | 65% | 9/26 | 35% | 12/26 | 46% | 13/26 | 50% | 16/26 | 62% |
| – Anaplastic oligoastrocytoma | 24/28 | 86% | 20/28 | 71% | 8/27 | 30% | 13/27 | 48% | 17/27 | 63% | 18/27 | 67% |
| Oligodendroglial tumors | 24/31 | 77% | 22/31 | 71% | 18/29 | 62% | 3/31 | 10% | 9/31 | 29% | 17/31 | 55% |
| – Oligodendroglioma | 14/18 | 78% | 13/18 | 72% | 10/16 | 63% | 1/18 | 6% | 4/18 | 22% | 9/18 | 50% |
| – Anaplastic oligodendroglioma | 10/13 | 77% | 9/13 | 69% | 8/13 | 62% | 2/13 | 15% | 5/13 | 38% | 8/13 | 62% |